How Much You Need To Expect You'll Pay For A Good Brr2-IN-3
Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as compared with imatinib, for the primary-line remedy of CML-CP. Five hundred and nineteen sufferers with freshly diagnosed CML-CP have been randomly assigned to obtain dasatinib in a dose of 100 mg after daily (259 patients) or imatinib in a dose of 400 mg when each day (260